HCW Biologics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HCWB Nasdaq 2836 www.hcwbiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for HCW Biologics Inc.

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen - May 27th, 2026 5:45 am
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement - May 22nd, 2026 2:02 pm
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules - May 21st, 2026 7:53 am
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners - May 18th, 2026 8:35 am
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results - May 14th, 2026 2:25 pm
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies - May 14th, 2026 5:30 am
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - Apr 30th, 2026 2:20 pm
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - Apr 27th, 2026 5:30 am
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - Mar 31st, 2026 3:05 pm
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - Mar 17th, 2026 5:50 am
BC-Most Active Stocks - Mar 16th, 2026 8:30 am
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Mar 16th, 2026 6:00 am
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Mar 2nd, 2026 6:00 am
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - Feb 19th, 2026 3:31 pm
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - Feb 17th, 2026 7:50 pm
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - Feb 13th, 2026 6:30 am
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules - Nov 19th, 2025 6:30 am
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - Nov 18th, 2025 5:25 am
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - Nov 14th, 2025 2:44 pm
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer - Nov 10th, 2025 5:00 am